Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Parkedale Turns To Consultants After FDA Halts Fluogen Production

Executive Summary

Parkedale Pharmaceuticals is drawing on advice from regulatory consultants The Biologics Consulting Group and regulatory legal counsel Arnold and Porter in "evaluating strategies pertaining to Fluogen," the company said.

You may also be interested in...



King Fluogen Discontinued; Flu Vaccine Would Have Been Unavailable In 2000

King Pharmaceuticals will discontinue Fluogen following receipt of a Sept. 27 FDA letter concerning the flu vaccine.

King Fluogen Discontinued; Flu Vaccine Would Have Been Unavailable In 2000

King Pharmaceuticals will discontinue Fluogen following receipt of a Sept. 27 FDA letter concerning the flu vaccine.

Powderject Moves Into Marketing Phase Via Medeva Vaccines Acquisition

Powderject's acquisition of Medeva's vaccines business moves the company from the research phase into the marketing of six products, one of which is sold in the U.S.

Related Content

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel